SMN2 and spinal muscular atrophy, type 1: However, in the absence of comparative data, in type 1 SMA and in pre-symptomatic patients with up to three copies of the SMN2 gene, HAS considers Spinraza® and Zolgensma® as first-line treatments; Evrysdi® can be used as first line in symptomatic patients with type 1 SMA, but has no place in pre-symptomatic setting.